336 related articles for article (PubMed ID: 18084322)
1. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
[TBL] [Abstract][Full Text] [Related]
2. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
3. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
Ejeskär K; Krona C; Carén H; Zaibak F; Li L; Martinsson T; Ioannou PA
BMC Cancer; 2005 Dec; 5():161. PubMed ID: 16359544
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
[TBL] [Abstract][Full Text] [Related]
5. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
[TBL] [Abstract][Full Text] [Related]
6. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
7. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
[TBL] [Abstract][Full Text] [Related]
9. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
10. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.
Alaminos M; Dávalos V; Ropero S; Setién F; Paz MF; Herranz M; Fraga MF; Mora J; Cheung NK; Gerald WL; Esteller M
Cancer Res; 2005 Apr; 65(7):2565-71. PubMed ID: 15805250
[TBL] [Abstract][Full Text] [Related]
11. CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23.
Michels E; Hoebeeck J; De Preter K; Schramm A; Brichard B; De Paepe A; Eggert A; Laureys G; Vandesompele J; Speleman F
BMC Cancer; 2008 Jun; 8():173. PubMed ID: 18559103
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease.
Grau E; Martinez F; Orellana C; Canete A; Yañez Y; Oltra S; Noguera R; Hernandez M; Bermúdez JD; Castel V
Mol Carcinog; 2011 Mar; 50(3):153-62. PubMed ID: 21104989
[TBL] [Abstract][Full Text] [Related]
13. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
15. Cell adhesion molecule 1 is a novel pancreatic-islet cell adhesion molecule that mediates nerve-islet cell interactions.
Koma Y; Furuno T; Hagiyama M; Hamaguchi K; Nakanishi M; Masuda M; Hirota S; Yokozaki H; Ito A
Gastroenterology; 2008 May; 134(5):1544-54. PubMed ID: 18471525
[TBL] [Abstract][Full Text] [Related]
16. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification.
Misawa A; Inoue J; Sugino Y; Hosoi H; Sugimoto T; Hosoda F; Ohki M; Imoto I; Inazawa J
Cancer Res; 2005 Nov; 65(22):10233-42. PubMed ID: 16288011
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.
Takahashi Y; Iwai M; Kawai T; Arakawa A; Ito T; Sakurai-Yageta M; Ito A; Goto A; Saito M; Kasumi F; Murakami Y
Breast Cancer; 2012 Jul; 19(3):242-52. PubMed ID: 21526423
[TBL] [Abstract][Full Text] [Related]
18. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation.
Zhang W; Zhou L; Ding SM; Xie HY; Xu X; Wu J; Chen QX; Zhang F; Wei BJ; Eldin AT; Zheng SS
Oncol Rep; 2011 Apr; 25(4):1053-62. PubMed ID: 21271221
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
